Sep 04, 2019
Infinity Pharmaceuticals Announces the Initiation of Two Clinical Trials Evaluating IPI-549 in Novel Triple Combination Therapies for the Treatment of Solid Tumors
Sep 03, 2019
Infinity to Present at Two Upcoming Conferences in September
Aug 22, 2019
Infinity Pharmaceuticals Announces Transition of Samuel Agresta, M.D., from Chief Medical Officer to Board of Directors
Jul 30, 2019
Infinity Pharmaceuticals Provides Company Update and Second Quarter 2019 Financial Results
Jul 23, 2019
Infinity Announces The Date Of Its Second Quarter 2019 Financial Results Conference Call And Webcast
May 29, 2019
Infinity Pharmaceuticals To Present At The 2019 BIO International Convention
May 16, 2019
Infinity Pharmaceuticals To Present At B. Riley FBR Institutional Investor Conference
May 07, 2019
Infinity Pharmaceuticals Provides Company Update and First Quarter 2019 Financial Results
Apr 30, 2019
Infinity Announces the Date of Its First Quarter 2019 Financial Results Conference Call and Webcast
Apr 02, 2019
Infinity Pharmaceuticals To Present At The 18th Annual Needham Healthcare Conference
Mar 14, 2019
Infinity Pharmaceuticals Reports Full Year 2018 Financial Results and Provides Company Update
Mar 14, 2019
Infinity To Initiate MARIO-3, A Phase 2 Multi-Arm Study Evaluating IPI-549 In Front-Line Triple Negative Breast Cancer And Renal Cell Cancer
Mar 07, 2019
Infinity Announces the Date of Its Full Year 2018 Financial Results Conference Call and Webcast
Mar 06, 2019
Infinity Pharmaceuticals Announces Royalty Monetization of COPIKTRA(TM) for $30 Million Gross Proceeds
Feb 04, 2019
Infinity Pharmaceuticals To Present At BIO CEO & Investor Conference
Jan 07, 2019
Infinity Pharmaceuticals Provides 2019 Goals and Financial Guidance
Jan 03, 2019
Infinity To Present At 37th Annual J.P. Morgan Healthcare Conference
Nov 10, 2018
Infinity Reports Clinical and Translational Data from Expansion Cohorts of MARIO-1 Phase 1b Study of IPI-549 in Combination with Opdivo® (nivolumab) at SITC's 33rd Annual Meeting
Nov 05, 2018
Bristol-Myers Squibb and Infinity Pharmaceuticals Announce a New Clinical Collaboration to Evaluate Opdivo (Nivolumab) in Combination with IPI-549 in Urothelial Cancer
Nov 05, 2018
Infinity Pharmaceuticals Provides Company Update and Third Quarter 2018 Financial Results